创新医疗公告：为子公司鸿润医药提供最高800万元连带责任担保，累计担保额度达5,120万元
2026年5月12日，创新医疗管理股份有限公司（证券代码：002173）发布公告，披露公司为全资控股子公司浙江鸿润医药有限公司（下称“鸿润医药”）提供担保的最新进展及相关细节。此次担保事项及其进展具有重要信息，投资者需高度关注。
一、担保事项的具体情况及进展
- 董事会审批：2026年4月28日，公司第七届董事会2026年第二次临时会议已审议通过《关于为鸿润医药提供担保的议案》。公司同意为鸿润医药在800万元授信额度内，向招商银行绍兴诸暨支行（下称“招商银行诸暨支行”）申请贷款提供担保。
- 担保合同签署：公司与招商银行诸暨支行已正式签署《最高额不可撤销担保书》（合同编号：571XY260421T00000201）。
- 担保内容：
- 债权人：招商银行诸暨支行
- 保证人：创新医疗管理股份有限公司
- 债务人：浙江鸿润医药有限公司
- 保证范围：最高担保额度为人民币800万元，涵盖贷款本金、利息、罚息、复息、违约金、迟延履行金、保理费用、实现担保权和债权的费用等所有相关费用。
- 担保方式：连带责任保证。
- 保证期间：自担保合同生效日起，至授信协议项下每笔贷款或其他融资到期日或垫款日后再加三年。若授信展期，担保期限亦相应顺延。
二、公司累计担保情况及合规性说明
- 累计担保额度：截至本公告日，公司累计为子公司提供担保总额为5,120万元，占公司最近一期经审计净资产的2.90%。所有对外担保均为对子公司担保，无为其他主体担保。
- 合规性及风险控制：公司目前不存在逾期担保、涉及诉讼的担保事项，同时除所披露外无其他对外担保事项。
三、投资者需重点关注的事项及潜在影响
- 此次800万元的连带责任担保，进一步提升了鸿润医药的融资能力，有助于其业务扩展，为公司整体业绩带来积极影响。担保额度和累计担保比例处于可控范围内，显示公司风险管理能力较强。
- 鉴于担保合同为连带责任，若鸿润医药出现还款风险，上市公司需承担担保责任，投资者需持续关注子公司经营情况及公司整体担保风险暴露。
- 本次公告无新增对外担保或担保逾期事项，也无相关诉讼风险，表明公司担保管理规范，短期内对股东权益影响有限。
四、备查文件
公司与招商银行诸暨支行签署的《最高额不可撤销担保书》（合同编号：571XY260421T00000201）。
结论
本次为子公司提供担保事项，虽在公司净资产内合理范围，但投资者需持续关注子公司经营及担保履约风险。此举有助于子公司融资，可能对公司未来业绩形成正面影响，具有一定的市场关注度和潜在股价影响。
免责声明：本文内容仅基于创新医疗公告文件整理，所含信息不构成投资建议。投资有风险，股市有风险，投资者需自行判断并注意风险防范。请以公司公告原文及后续披露为准。
INNOVATION MEDICAL: Provides RMB 8 Million Guarantee for Subsidiary Hongrun Pharmaceutical, Total Guarantees Reaches RMB 51.2 Million
On May 12, 2026, Innovation Medical Management Co., Ltd. (002173) announced it has signed an irrevocable maximum guarantee letter for its wholly-owned subsidiary Zhejiang Hongrun Pharmaceutical Co., Ltd. (“Hongrun Pharmaceutical”), marking a noteworthy event for investors regarding the company’s financial commitments and risk profile.
1. Details and Progress of the Guarantee
- Board Approval: On April 28, 2026, the Board approved a proposal to provide a guarantee for Hongrun Pharmaceutical’s loan application of up to RMB 8 million with China Merchants Bank Zhuji Branch.
- Guarantee Contract Signing: The company has officially signed an “Irrevocable Maximum Guarantee Letter” (Contract No.: 571XY260421T00000201) with China Merchants Bank Zhuji Branch.
- Guarantee Details:
- Creditor: China Merchants Bank Zhuji Branch
- Guarantor: Innovation Medical Management Co., Ltd.
- Debtor: Zhejiang Hongrun Pharmaceutical Co., Ltd.
- Scope: Up to RMB 8 million covering principal, interest, penalty interest, compound interest, liquidated damages, overdue execution fees, factoring fees, costs to realize the guarantee and debt, and other related expenses.
- Type: Joint liability guarantee.
- Term: From the effective date until three years after the maturity or repayment of each loan/funding, and if extended, three years after the extension period ends.
2. Cumulative Guarantee Status and Compliance
- Total Guarantee Amount: The cumulative guarantee for subsidiaries now stands at RMB 51.2 million, or 2.90% of the company’s latest audited net assets. All guarantees are for subsidiaries; none for unrelated parties.
- Risk & Compliance: No overdue guarantees, no guarantee-related litigation, and no undisclosed guarantees. The company maintains prudent guarantee risk controls.
3. Key Points for Investors & Potential Impact
- This RMB 8 million joint liability guarantee boosts Hongrun Pharmaceutical’s financing capabilities, supporting business expansion and potentially benefiting group performance.
- As a joint liability guarantee, the parent company will be responsible if the subsidiary defaults. Investors should monitor both the subsidiary’s financial health and the group’s guarantee exposure.
- No new overdue guarantees or litigation risks were disclosed, indicating sound guarantee management. Immediate impact on shareholder interests is limited but positive for subsidiary growth.
4. Reference Documents
Signed irrevocable maximum guarantee letter with China Merchants Bank Zhuji Branch (Contract No.: 571XY260421T00000201).
Conclusion
The new guarantee, while within the company’s asset tolerance, raises the group’s guarantee exposure and supports subsidiary growth. Investors should pay attention to future subsidiary performance and guarantee risk, as this development may influence market sentiment and share price.
Disclaimer: This article is for information only, based on Innovation Medical’s official disclosures. It does not constitute investment advice. Investors should make their own decisions and be aware of risks. Please refer to official announcements for updates.
